<DOC>
	<DOCNO>NCT02864381</DOCNO>
	<brief_summary>The primary objective study evaluate compare efficacy andecaliximab ( GS-5745 ) combination nivolumab versus nivolumab alone adults recurrent gastric gastroesophageal junction ( GEJ ) adenocarcinoma .</brief_summary>
	<brief_title>Andecaliximab Combined With Nivolumab Versus Nivolumab Alone Adults With Unresectable Recurrent Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Histologically confirm inoperable locally advanced metastatic adenocarcinoma stomach GEJ progress least 1 prior systemic therapy line treatment unresectable/metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 1 Measurable disease accord RECIST v1.1 Tumor sit accessed repeat biopsy Archival tumor tissue , preferably obtain recent available biopsy ; must adequate tissue PDL1 stratification test , assessed central pathologist Individuals receive anticoagulant medication must international normalize ratio ( INR ) ≤ 1.5 activate partial thromboplastin ( aPTT ) ≤ 1.5 x upper limit normal ( ULN ) Required baseline laboratory data outline protocol Key Individuals receive neoadjuvant adjuvant therapy gastric adenocarcinoma Radiotherapy within 28 day randomization Uncontrolled intercurrent illness outline protocol History concurrent second malignancy except outline protocol Major surgery , within 28 day first dose study drug Known positive status human immunodeficiency virus ( HIV ) Known acute chronicactive infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Chronic daily treatment oral corticosteroid ( dose &gt; 10 mg/day prednisone equivalent ) immunosuppressive medication within 14 day randomization Known suspect central nervous system metastasis Documented myocardial infarction unstable/uncontrolled cardiac disease within 6 month randomization Serious systemic fungal , bacterial , viral , infection control require intravenous antibiotic Current history pneumonitis interstitial lung disease Active know suspect autoimmune disease exception note protocol . History bone marrow , stem cell , allogenic organ transplantation NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>